{"id":"nimodipine","rwe":[{"pmid":"41886253","year":"2026","title":"Commentary on: \"Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage\".","finding":"","journal":"Neurocritical care","studyType":"Clinical Study"},{"pmid":"41886251","year":"2026","title":"Response to Letter by Michael Veldeman Regarding Article \"Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage\".","finding":"","journal":"Neurocritical care","studyType":"Clinical Study"},{"pmid":"41882452","year":"2026","title":"Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.","finding":"","journal":"Neurosurgical review","studyType":"Clinical Study"},{"pmid":"41855149","year":"2026","title":"Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"41843337","year":"2026","title":"Unrevealing possible mechanism of Riluzole, Salsalate and Nimodipine in Alzheimer's disease: multi-target network pharmacological perspective.","finding":"","journal":"Inflammopharmacology","studyType":"Clinical Study"}],"_fda":{"id":"05594f64-8cb4-4cc0-b1b9-93fb5313b197","set_id":"a323ebd8-ef1b-439b-93d1-ba73a5b0127d","openfda":{"nui":["N0000000069","N0000175421","M0006414"],"unii":["57WA9QZ5WH"],"route":["ORAL"],"rxcui":["198037"],"spl_id":["05594f64-8cb4-4cc0-b1b9-93fb5313b197"],"brand_name":["nimodipine"],"spl_set_id":["a323ebd8-ef1b-439b-93d1-ba73a5b0127d"],"package_ndc":["23155-512-30","23155-512-00"],"product_ndc":["23155-512"],"generic_name":["NIMODIPINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Dihydropyridines [CS]"],"substance_name":["NIMODIPINE"],"pharm_class_epc":["Dihydropyridine Calcium Channel Blocker [EPC]"],"pharm_class_moa":["Calcium Channel Antagonists [MoA]"],"manufacturer_name":["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."],"application_number":["ANDA077811"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS DEATH DUE TO INADVERTENT INTRAVENOUS ADMINISTRATION: DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE THREATENING ADVERSE EVENTS, INCLUDING CARDIAC ARREST, CARDIOVASCULAR COLLAPSE, HYPOTENSION, AND BRADYCARDIA, HAVE OCCURRED WHEN THE CONTENTS OF NIMODIPINE CAPSULES HAVE BEEN INJECTED PARENTERALLY (SEE DOSAGE AND ADMINISTRATION ). Reduced Efficacy with CYP3A4 Inducers: Concomitant use of strong CYP3A4 inducers (e.g. rifampin, phenobarbital, phenytoin, carbamazepine, St John's wort) and nimodipine should generally be avoided, as nimodipine plasma concentration and efficacy may be very significantly reduced (see PRECAUTIONS, Drug Interactions ). Moderate and weak inducers of CYP3A4 may also reduce the efficacy of nimodipine to a lesser extent. Patients on these should be closely monitored for lack of effectiveness, and a nimodipine dosage increase may be required. Moderate and weak CYP3A4 inhibitors include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirenz, etravirine, echinacea, modafinil, nafcillin, pioglitazone, prednisone and rufinamide."],"overdosage":["OVERDOSAGE There have been no reports of overdosage from the oral administration of nimodipine. Symptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension. Clinically significant hypotension due to nimodipine overdosage may require active cardiovascular support with pressor agents. Specific treatments for calcium channel blocker overdose should also be given promptly. Since nimodipine is highly protein-bound, dialysis is not likely to be of benefit."],"description":["DESCRIPTION Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-( m -nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C 21 H 26 N 2 O 7 . The structural formula is: Nimodipine is a yellow crystalline substance, practically insoluble in water. Nimodipine capsules are formulated as soft gelatin capsules for oral administration. Each liquid filled capsule contains 30 mg of nimodipine in a vehicle of glycerin, peppermint oil and polyethylene glycol. The gelatin shell contains FD&C Yellow No. 6 Aluminum Lake, gelatin, glycerin, iron oxide black, lecithin, medium-chain triglycerides, shellac, sorbitol and titanium dioxide. structure"],"precautions":["PRECAUTIONS General Blood Pressure: Nimodipine has the hemodynamic effects expected of a calcium channel blocker, although they are generally not marked. However, intravenous administration of the contents of nimodipine capsules has resulted in serious adverse consequences including death, cardiac arrest, cardiovascular collapse, hypotension, and bradycardia. In patients with subarachnoid hemorrhage given nimodipine in clinical studies, about 5% were reported to have had lowering of the blood pressure and about 1% left the study because of this (not all could be attributed to nimodipine). Nevertheless, blood pressure should be carefully monitored during treatment with nimodipine based on its known pharmacology and the known effects of calcium channel blockers. (see WARNINGS and DOSAGE AND ADMINISTRATION ). Hepatic Disease: The metabolism of nimodipine is decreased in patients with impaired hepatic function. Such patients should have their blood pressure and pulse rate monitored closely and should be given a lower dose (see DOSAGE AND ADMINISTRATION ). Intestinal pseudo-obstruction and ileus have been reported rarely in patients treated with nimodipine. A causal relationship has not been established. The condition has responded to conservative management. Laboratory Test Interactions None known. Drug Interactions Nimodipine is metabolized via the cytochrome P450 3A4 system located both in the intestinal mucosa and in the liver. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass or the clearance of nimodipine. In addition, the blood pressure lowering effects of antihypertensives could be enhanced when taken concomitantly with nimodipine. Inducers of CYP3A4: Nimodipine plasma concentration and efficacy may be significantly reduced when concomitantly administered with strong CYP3A4 inducers. Therefore strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenobarbital, phenytoin, St. John's Wort) should generally not be administered concomitantly with nimodipine (see WARNINGS ). Other moderate and weak inducers of CYP3A4 may also reduce the efficacy of nimodipine, although the magnitude of decrease in nimodipine plasma concentrations is not known. Patients on these should be closely monitored for lack of effectiveness, and a nimodipine dosage increase may be required. Moderate and weak CYP3A4 inducers include: amprenavir, aprepitant, armodafinil, bosentan, efavirenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone and rufinamide. Inhibitors of CYP3A4: Nimodipine plasma concentration can be significantly increased when concomitantly administered with strong inhibitors of the CYP3A4 system. As a consequence, the blood pressure lowering effect may be increased. Therefore strong CYP3A4 inhibitors should not be coadministered with nimodipine (see CONTRAINDICATIONS ). Strong CYP3A4 inhibitors include some members of the following classes: - macrolide antibiotics (e.g., clarithromycin, telithromycin), -HIV protease inhibitors (e.g., delavirdine, indinavir, nelfinavir, ritonavir, saquinavir), - azole antimycotics (e.g., ketoconazole, itraconazole, voriconazole), - antidepressants (e.g. nefazodone) - grapefruit juice: after intake of grapefruit juice and nimodipine, the blood pressure lowering effect may last for at least 4 days after the last ingestion of grapefruit juice. Ingestion of grapefruit/grapefruit juice is therefore not recommended while taking nimodipine (see DOSAGE AND ADMINISTRATION ). Nimodipine plasma concentration can also be increased in the presence of moderate and weak inhibitors of CYP3A4. If nimodipine is concomitantly administered with these drugs, blood pressure should be monitored, and a reduction of the nimodipine dose may be necessary. Moderate and weak CYP3A4 inhibitors include amprenavir, aprepitant, atazanavir, amiodarone, alprozalam, cyclosporine, cimetidine, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinuprestin/dalforpristin, and valproic acid. Blood pressure lowering drugs: Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives, such as: – diuretics, – β-blockers, – ACE inhibitors, – A1-antagonists, – other calcium antagonists, – α-adrenergic blocking agents, – PDE5 inhibitors, – α-methyldopa. Blood pressure should be carefully monitored, and dose adjustment of the blood pressure lowering drug(s) may be necessary. Carcinogenesis, Mutagenesis, Impairment of Fertility In a two-year study, higher incidences of adenocarcinoma of the uterus and Leydig-cell adenoma of the testes were observed in rats given a diet containing 1800 ppm nimodipine (equivalent to 91 to 121 mg/kg/day nimodipine) than in placebo controls. The differences were not statistically significant, however, and the higher rates were well within historical control range for these tumors in the Wistar strain. Nimodipine was found not to be carcinogenic in a 91-week mouse study but the high dose of 1800 ppm nimodipine-in-feed (546 to 774 mg/kg/day) shortened the life expectancy of the animals. Mutagenicity studies, including the Ames, micronucleus and dominant lethal tests were negative. Nimodipine did not impair the fertility and general reproductive performance of male and female Wistar rats following oral doses of up to 30 mg/kg/day when administered daily for more than 10 weeks in the males and 3 weeks in the females prior to mating and continued to day 7 of pregnancy. This dose in a rat is about 4 times the equivalent clinical dose of 60 mg q4h in a 50 kg patient. Pregnancy Nimodipine has been shown to have a teratogenic effect in Himalayan rabbits. Incidences of malformations and stunted fetuses were increased at oral doses of 1 and 10 mg/kg/day administered (by gavage) from day 6 through day 18 of pregnancy but not at 3 mg/kg/day in one of two identical rabbit studies. In the second study an increased incidence of stunted fetuses was seen at 1 mg/kg/day but not at higher doses. Nimodipine was embryotoxic, causing resorption and stunted growth of fetuses, in Long Evans rats at 100 mg/kg/day administered by gavage from day 6 through day 15 of pregnancy. In two other rat studies, doses of 30 mg/kg/day nimodipine administered by gavage from day 16 of gestation and continued until sacrifice (day 20 of pregnancy or day 21 post partum) were associated with higher incidences of skeletal variation, stunted fetuses and stillbirths but no malformations. There are no adequate and well controlled studies in pregnant women to directly assess the effect on human fetuses. Nimodipine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Nimodipine and/or its metabolites have been shown to appear in rat milk at concentrations much higher than in maternal plasma. It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, nursing mothers are advised not to breast feed their babies when taking the drug. Pediatric Use Safety and effectiveness in children have not been established. Geriatric Use Clinical studies of nimodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dosing in elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Nimodipine Capsules 30 mg are available as orange, opaque, oblong shape, soft gelatin capsules, imprinted \"HP 512\" with black ink. They are supplied as follows: Strength NDC Code Unit Dose Package of 30: (3 blister cards; each containing 10 capsules) 30 mg 23155-512-30 Unit Dose Package of 100: (10 blister cards; each containing 10 capsules) 30 mg 23155-512-00 The capsules should be stored in the manufacturer's original package. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Capsules should be protected from light and freezing. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000272US03 Revised: 06/2024 avet-logo"],"boxed_warning":["DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMODIPINE CAPSULES HAVE BEEN INJECTED PARENTERALLY (See WARNINGS and DOSAGE AND ADMINISTRATION )."],"effective_time":"20240816","adverse_reactions":["ADVERSE REACTIONS Adverse experiences were reported by 92 of 823 patients with subarachnoid hemorrhage (11.2%) who were given nimodipine. The most frequently reported adverse experience was decreased blood pressure in 4.4% of these patients. Twenty-nine of 479 (6.1%) placebo treated patients also reported adverse experiences. The events reported with a frequency greater than 1% are displayed below by dose. DOSE q4h Number of Patients (%) Nimodipine Sign/Symptom 0.35 mg/kg (n=82) 30 mg (n=71) 60 mg (n=494) 90 mg (n=172) 120 mg (n=4) Placebo (n=479) Decreased Blood Pressure 1 (1.2) 0 19 (3.8) 14 (8.1) 2 (50.0) 6 (1.2) Abnormal Liver Function Test 1 (1.2) 0 2 (0.4) 1 (0.6) 0 7 (1.5) Edema 0 0 2 (0.4) 2 (1.2) 0 3 (0.6) Diarrhea 0 3 (4.2) 0 3 (1.7) 0 3 (0.6) Rash 2 (2.4) 0 3 (0.6) 2 (1.2) 0 3 (0.6) Headache 0 1 (1.4) 6 (1.2) 0 0 1 (0.2) Gastrointestinal Symptoms 2 (2.4) 0 0 2 (1.2) 0 0 Nausea 1 (1.2) 1 (1.4) 6 (1.2) 1 (0.6) 0 0 Dyspnea 1 (1.2) 0 0 0 0 0 EKG Abnormalities 0 1 (1.4) 0 1 (0.6) 0 0 Tachycardia 0 1 (1.4) 0 0 0 0 Bradycardia 0 0 5 (1.0) 1 (0.6) 0 0 Muscle Pain/Cramp 0 1 (1.4) 1 (0.2) 1 (0.6) 0 0 Acne 0 1 (1.4) 0 0 0 0 Depression 0 1 (1.4) 0 0 0 0 There were no other adverse experiences reported by the patients who were given 0.35 mg/kg q4h, 30 mg q4h or 120 mg q4h. Adverse experiences with an incidence rate of less than 1% in the 60 mg q4h dose group were: hepatitis; itching; gastrointestinal hemorrhage; thrombocytopenia; anemia; palpitations; vomiting; flushing; diaphoresis; wheezing; phenytoin toxicity; lightheadedness; dizziness; rebound vasospasm; jaundice; hypertension; hematoma. Adverse experiences with an incidence rate less than 1% in the 90 mg q4h dose group were: itching, gastrointestinal hemorrhage; thrombocytopenia; neurological deterioration; vomiting; diaphoresis; congestive heart failure; hyponatremia; decreasing platelet count; disseminated intravascular coagulation; deep vein thrombosis. As can be seen from the table, side effects that appear related to nimodipine use based on increased incidence with higher dose or a higher rate compared to placebo control, included decreased blood pressure, edema and headaches which are known pharmacologic actions of calcium channel blockers. It must be noted, however, that SAH is frequently accompanied by alterations in consciousness which lead to an under reporting of adverse experiences. Patients who received nimodipine in clinical trials for other indications reported flushing (2.1%), headache (4.1%) and fluid retention (0.3%), typical responses to calcium channel blockers. As a calcium channel blocker, nimodipine may have the potential to exacerbate heart failure in susceptible patients or to interfere with A-V conduction, but these events were not observed. No clinically significant effects on hematologic factors, renal or hepatic function or carbohydrate metabolism have been causally associated with oral nimodipine. Isolated cases of non-fasting elevated serum glucose levels (0.8%), elevated LDH levels (0.4%), decreased platelet counts (0.3%), elevated alkaline phosphatase levels (0.2%) and elevated SGPT levels (0.2%) have been reported rarely. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS The concomitant use of nimodipine with strong inhibitors of CYP3A4 such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some anti-HIV protease inhibitors (e.g., delaviridine, indinavir, nelfinavir, ritonavir, saquinavir), some azole antimycotics (e.g., ketoconazole, itraconazole, voriconazole) and some antidepressants (e.g., nefazadone) is contraindicated because of a risk of significant hypotension (see PRECAUTIONS, Drug Interactions )."],"how_supplied_table":["
Strength NDC Code
Unit Dose Package of 30: (3 blister cards; each containing 10 capsules)30 mg23155-512-30
Unit Dose Package of 100: (10 blister cards; each containing 10 capsules)30 mg23155-512-00
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mechanism of Action Nimodipine is a calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood-brain barrier; concentrations of nimodipine as high as 12.5 ng/mL have been detected in the cerebrospinal fluid of nimodipine-treated subarachnoid hemorrhage (SAH) patients. The precise mechanism of action of nimodipine in humans is unknown. Although the clinical studies described below demonstrate a favorable effect of nimodipine on the severity of neurological deficits caused by cerebral vasospasm following SAH, there is no arteriographic evidence that the drug either prevents or relieves the spasm of these arteries. However, whether or not the arteriographic methodology utilized was adequate to detect a clinically meaningful effect, if any, on vasospasm is unknown. Pharmacokinetics and Metabolism In man, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. The terminal elimination half-life is approximately 8 to 9 hours but earlier elimination rates are much more rapid, equivalent to a half-life of 1 to 2 hours; a consequence is the need for frequent (every 4 hours) dosing. There were no signs of accumulation when nimodipine was given three times a day for seven days. Nimodipine is over 95% bound to plasma proteins. The binding was concentration independent over the range of 10 ng/mL to 10 mcg/mL. Nimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug. Numerous metabolites, all of which are either inactive or considerably less active than the parent compound, have been identified. The metabolism of nimodipine is mediated by CYP3A4. Because of a high first-pass metabolism, the bioavailability of nimodipine averages 13% after oral administration. The bioavailability is significantly increased in patients with hepatic cirrhosis, with C max approximately double that in normals which necessitates lowering the dose in this group of patients (see DOSAGE AND ADMINISTRATION ). In a study of 24 healthy male volunteers, administration of nimodipine capsules following a standard breakfast resulted in a 68% lower peak plasma concentration and 38% lower bioavailability relative to dosing under fasted conditions. In a single parallel-group study involving 24 elderly subjects (aged 59 to 79) and 24 younger subjects (aged 22 to 40), the observed AUC and C max of nimodipine was approximately 2-fold higher in the elderly population compared to the younger study subjects following oral administration (given as a single dose of 30 mg and dosed to steady-state with 30 mg t.i.d. for 6 days). The clinical response to these age-related pharmacokinetic differences, however, was not considered significant. (See PRECAUTIONS: Geriatric Use. ) Clinical Trials Nimodipine has been shown, in 4 randomized, double-blind, placebo-controlled trials, to reduce the severity of neurological deficits resulting from vasospasm in patients who have had a recent subarachnoid hemorrhage (SAH). The trials used doses ranging from 20–30 mg to 90 mg every 4 hours, with drug given for 21 days in 3 studies, and for at least 18 days in the other. Three of the four trials followed patients for 3 to 6 months. Three of the trials studied relatively well patients, with all or most patients in Hunt and Hess Grades I to III (essentially free of focal deficits after the initial bleed) the fourth studied much sicker patients, Hunt and Hess Grades III to V. Two studies, one U.S., one French, were similar in design, with relatively unimpaired SAH patients randomized to nimodipine or placebo. In each, a judgment was made as to whether any late-developing deficit was due to spasm or other causes, and the deficits were graded. Both studies showed significantly fewer severe deficits due to spasm in the nimodipine group; the second (French) study showed fewer spasm-related deficits of all severities. No effect was seen on deficits not related to spasm. * Hunt and Hess Grade ** p=0.03 Patients Study Dose Grade* Number Analyzed Any Deficit Due to Spasm Numbers with Severe Deficit U.S. 20 to 30 mg I to III Nimodipine Placebo 56 60 13 16 1 8** French 60 mg I to III Nimodipine Placebo 31 39 4 11 2 10** A third, large, study was performed in the United Kingdom in SAH patients with all grades of severity (but 89% were in Grades I to III). Nimodipine was dosed 60 mg every 4 hours. Outcomes were not defined as spasm related or not but there was a significant reduction in the overall rate of infarction and severely disabling neurological outcome at 3 months: * p=0.0444 - good and moderate vs severe and dead ** p=0.001 - severe disability *** p=0.056 - death Nimodipine Placebo Total patients 278 276 Good recovery 199* 169 Moderate disability 24 16 Severe disability 12** 31 Death 43*** 60 A Canadian study entered much sicker patients, (Hunt and Hess Grades III to V), who had a high rate of death and disability, and used a dose of 90 mg every 4 hours, but was otherwise similar to the first two studies. Analysis of delayed ischemic deficits, many of which result from spasm, showed a significant reduction in spasm-related deficits. Among analyzed patients (72 nimodipine, 82 placebo), there were the following outcomes. * p = 0.001, nimodipine vs placebo Delayed Ischemic Deficits (DID) Permanent Deficits Nimodipine n (%) Placebo n (%) Nimodipine n (%) Placebo n (%) DID Spasm Alone 8 (11)* 25 (31) 5 (7)* 22 (27) DID Spasm Contributing 18 (25) 21 (26) 16 (22) 17 (21) DID Without Spasm 7 (10) 8 (10) 6 (8) 7 (9) No DID 39 (54) 28 (34) 45 (63) 36 (44) When data were combined for the Canadian and the United Kingdom studies, the treatment difference on success rate (i.e., good recovery) on the Glasgow Outcome Scale was 25.3% (nimodipine) versus 10.9% (placebo) for Hunt and Hess Grades IV or V. The table below demonstrates that nimodipine tends to improve good recovery of SAH patients with poor neurological status post-ictus, while decreasing the numbers with severe disability and vegetative survival. * p = 0.045, nimodipine vs placebo Glasgow Outcome* Nimodipine (n=87) Placebo (n=101) Good Recovery 22 (25.3%) 11 (10.9%) Moderate Disability 8 (9.2%) 12 (11.9%) Severe Disability 6 (6.9%) 15 (14.9%) Vegetative Survival 4 (4.6%) 9 (8.9%) Death 47 (54.0%) 54 (53.5%)"],"indications_and_usage":["INDICATIONS AND USAGE Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I to V)."],"adverse_reactions_table":["
DOSE q4h Number of Patients (%) Nimodipine
Sign/Symptom 0.35 mg/kg (n=82) 30 mg (n=71) 60 mg (n=494) 90 mg (n=172) 120 mg (n=4) Placebo (n=479)
Decreased
Blood Pressure 1 (1.2) 0 19 (3.8) 14 (8.1) 2 (50.0) 6 (1.2)
Abnormal Liver
Function Test 1 (1.2) 0 2 (0.4) 1 (0.6) 0 7 (1.5)
Edema 0 0 2 (0.4) 2 (1.2) 0 3 (0.6)
Diarrhea 0 3 (4.2) 0 3 (1.7) 0 3 (0.6)
Rash 2 (2.4) 0 3 (0.6) 2 (1.2) 0 3 (0.6)
Headache 0 1 (1.4) 6 (1.2) 0 0 1 (0.2)
Gastrointestinal
Symptoms 2 (2.4) 0 0 2 (1.2) 0 0
Nausea 1 (1.2) 1 (1.4) 6 (1.2) 1 (0.6) 0 0
Dyspnea 1 (1.2) 0 0 0 0 0
EKG Abnormalities 0 1 (1.4) 0 1 (0.6) 0 0
Tachycardia 0 1 (1.4) 0 0 0 0
Bradycardia 0 0 5 (1.0) 1 (0.6) 0 0
Muscle Pain/Cramp 0 1 (1.4) 1 (0.2) 1 (0.6) 0 0
Acne 0 1 (1.4) 0 0 0 0
Depression 0 1 (1.4) 0 0 0 0
"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION DO NOT ADMINISTER NIMODIPINE CAPSULES INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES (see WARNINGS ). If nimodipine is inadvertently administered intravenously, clinically significant hypotension may require cardiovascular support with pressor agents. Specific treatments for calcium channel blocker overdose should also be given promptly. Nimodipine is given orally in the form of soft gelatin 30 mg capsules for subarachnoid hemorrhage. The recommended oral dose is 60 mg (two 30 mg capsules) every 4 hours for 21 consecutive days. In general, the capsules should be swallowed whole with a little liquid, preferably not less than one hour before or two hours after meals. Grapefruit juice is to be avoided (see PRECAUTIONS, Drug Interactions ). Oral nimodipine therapy should commence as soon as possible within 96 hours of the onset of subarachnoid hemorrhage. If the capsule cannot be swallowed, e.g., at the time of surgery, or if the patient is unconscious, a hole should be made in both ends of the capsule with an 18 gauge needle, and the contents of the capsule extracted into a syringe. A parenteral syringe can be used to extract the liquid inside the capsule, but the liquid should always be transferred to a syringe that cannot accept a needle and that is designed for administration orally or via a naso-gastric tube or PEG. To help minimize administration errors, it is recommended that the syringe used for administration be labeled \"Not for IV Use\". The contents should then be emptied into the patient's in situ naso-gastric tube and washed down the tube with 30 mL of normal saline (0.9%). Severely disturbed liver function, particularly liver cirrhosis, may result in an increased bioavailability of nimodipine due to a decreased first pass capacity and a reduced metabolic clearance. The reduction in blood pressure and other adverse effects may be more pronounced in these patients. Dosage should be reduced to one 30 mg capsule every 4 hours with close monitoring of blood pressure and heart rate; if necessary, discontinuation of the treatment should be considered. Strong inhibitors of CYP3A4 should not be administered concomitantly with nimodipine (see CONTRAINDICATIONS ). Strong inducers of CYP3A4 should generally not be administered with nimodipine (see WARNINGS ). Patients on moderate and weak inducers of CYP3A4 should be closely monitored for lack of effectiveness, and a nimodipine dose increase may be required. Patients on moderate and weak CYP3A4 inhibitors may require a nimodipine dose reduction in case of hypotension (see PRECAUTIONS, Drug Interactions )."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE There have been no reported instances of drug abuse or dependence with nimodipine."],"spl_product_data_elements":["nimodipine nimodipine NIMODIPINE NIMODIPINE GELATIN PEPPERMINT OIL GLYCERIN TITANIUM DIOXIDE SORBITOL SHELLAC FERROSOFERRIC OXIDE MEDIUM-CHAIN TRIGLYCERIDES FD&C YELLOW NO. 6 ALUMINUM LAKE POLYETHYLENE GLYCOL 400 SOYBEAN LECITHIN HP512"],"clinical_pharmacology_table":["
* Hunt and Hess Grade
** p=0.03
Patients
Study Dose Grade* Number Analyzed Any Deficit Due to Spasm Numbers with Severe Deficit
U.S.20 to 30 mgI to IIINimodipine Placebo56 6013 161 8**
French60 mgI to IIINimodipine Placebo31 394 112 10**
","
* p=0.0444 - good and moderate vs severe and dead
** p=0.001 - severe disability
*** p=0.056 - death
Nimodipine Placebo
Total patients278276
Good recovery199*169
Moderate disability2416
Severe disability12**31
Death43***60
","
* p = 0.001, nimodipine vs placebo
Delayed Ischemic Deficits (DID) Permanent Deficits
Nimodipine n (%) Placebo n (%) Nimodipine n (%) Placebo n (%)
DID Spasm Alone8 (11)*25 (31)5 (7)*22 (27)
DID Spasm Contributing18 (25)21 (26)16 (22)17 (21)
DID Without Spasm7 (10)8 (10)6 (8)7 (9)
No DID39 (54)28 (34)45 (63)36 (44)
","
* p = 0.045, nimodipine vs placebo
Glasgow Outcome* Nimodipine (n=87) Placebo (n=101)
Good Recovery22 (25.3%)11 (10.9%)
Moderate Disability8 (9.2%)12 (11.9%)
Severe Disability6 (6.9%)15 (14.9%)
Vegetative Survival4 (4.6%)9 (8.9%)
Death47 (54.0%)54 (53.5%)
"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 23155- 512 -30 Nimodipine Capsules 30 mg Contents are Packaged Child-Resistant. FOR ORAL USE ONLY 30 Unit-Dose Capsules 3 Blister Cards of 10 Capsules Rx only NDC 23155- 512 -00 Nimodipine Capsules 30 mg FOR INSTITUTIONAL USE ONLY Contents are Packaged Child-Resistant. FOR ORAL USE ONLY 100 Unit-Dose Capsules 10 Blister Cards of 10 Capsules Rx only carton-30 carton-100"]},"tags":[{"label":"Dihydropyridine Calcium Channel Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent L-type calcium channel subunit alpha-1F","category":"target"},{"label":"CACNA1F","category":"gene"},{"label":"NR3C2","category":"gene"},{"label":"NR1I2","category":"gene"},{"label":"C08CA06","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Solution","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Subarachnoid intracranial hemorrhage","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMODIPINE CAPSULES HAVE BEEN INJECTED PARENTERALLY (See WARNINGS and DOSAGE AND ADMINISTRATION )."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"85 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"71 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"SUBARACHNOID HAEMORRHAGE","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"RENAL FAILURE","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME","source":"FDA FAERS","actionTaken":"29 reports"}],"drugInteractions":[{"url":"/drug/carbamazepine","drug":"carbamazepine","action":"Avoid combination","effect":"May interact with Carbamazepine","source":"DrugCentral","drugSlug":"carbamazepine"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Monitor closely","effect":"May interact with Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/phenobarbital","drug":"phenobarbital","action":"Avoid combination","effect":"May interact with Phenobarbital","source":"DrugCentral","drugSlug":"phenobarbital"},{"url":"/drug/primidone","drug":"primidone","action":"Avoid combination","effect":"May interact with Primidone","source":"DrugCentral","drugSlug":"primidone"}],"commonSideEffects":[{"effect":"Decreased Blood Pressure","drugRate":"4.4%","severity":"common","_validated":true},{"effect":"Edema","drugRate":"3.8%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"1.4%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Tachycardia","drugRate":"1.2%","severity":"mild","_validated":true},{"effect":"Bradycardia","drugRate":"1.0%","severity":"mild","_validated":true},{"effect":"Muscle Pain/Cramp","drugRate":"1.0%","severity":"mild","_validated":true},{"effect":"Abnormal Liver Function Test","drugRate":"0.8%","severity":"mild","_validated":true},{"effect":"Acne","drugRate":"0.6%","severity":"mild","_validated":true},{"effect":"EKG Abnormalities","drugRate":"0.6%","severity":"mild","_validated":true},{"effect":"Gastrointestinal Symptoms","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Itching","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal Hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Anemia","drugRate":"reported","severity":"unknown"},{"effect":"Palpitations","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Flushing","drugRate":"reported","severity":"unknown"},{"effect":"Diaphoresis","drugRate":"reported","severity":"unknown"},{"effect":"Wheezing","drugRate":"reported","severity":"unknown"},{"effect":"Phenytoin Toxicity","drugRate":"reported","severity":"unknown"},{"effect":"Lightheadedness","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Rebound Vasospasm","drugRate":"reported","severity":"unknown"},{"effect":"Jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Hypertension","drugRate":"reported","severity":"unknown"}],"contraindications":["Chronic idiopathic constipation","Disease of liver","Low blood pressure"],"specialPopulations":{"Pregnancy":"Based on animal data may cause fetal harm. There are no adequate data on the developmental risk associated with the use of NYMALIZE in pregnant women. Nimodipine has been shown to have teratogenic effect in two studies in rabbit. The lowest effect dose in rabbits (1 mg/kg/day) is less than the recommended human dose (RHD) of 360 mg/day on body surface area (mg/m2) basis.","Geriatric use":"Clinical studies of nimodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dosing in elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease of other drug therapy.","Paediatric use":"Safety and effectiveness in children have not been established."}},"trials":[],"aliases":[],"patents":[{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"U-2804","territory":"US","drugProduct":true,"patentNumber":"11413277","drugSubstance":false},{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"U-2804","territory":"US","drugProduct":true,"patentNumber":"12186308","drugSubstance":false},{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"U-2804","territory":"US","drugProduct":true,"patentNumber":"10342787","drugSubstance":false},{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"U-2804","territory":"US","drugProduct":true,"patentNumber":"10576070","drugSubstance":false},{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"U-2804","territory":"US","drugProduct":false,"patentNumber":"11207306","drugSubstance":false},{"applNo":"N203340","source":"FDA Orange Book","status":"Active","expires":"Apr 16, 2038","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11806338","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.9946/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$363","description":"NIMODIPINE 30 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NIMODIPINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:40:20.752690+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:40:20.752538+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:40:27.496344+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:40:19.265652+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIMODIPINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:40:28.278172+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:18.176586+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:18.176607+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMODIPINE CAPSULES HAVE BEEN INJECTED PARENTERALLY (See WARNINGS and DOSAGE AND ADMINISTRATION ).","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:18.176614+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:40:29.781458+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Voltage-gated L-type calcium channel blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:40:28.852825+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1428/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:40:28.748877+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA077811","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:40:18.176619+00:00"}},"allNames":"nimotop","offLabel":[],"synonyms":["nimodipine","nemotan","nymalize"],"timeline":[{"date":"1988-12-28","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2007-04-17","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Nimotop (Nimodipine) is a dihydropyridine calcium channel blocker, a small molecule modality targeting the voltage-dependent L-type calcium channel subunit alpha-1F. It was originally developed and is currently owned by Azurity. FDA approved in 1988 for the treatment of subarachnoid intracranial hemorrhage, Nimotop is available as a generic medication with multiple manufacturers. Key safety considerations include its short half-life of 1.3 hours and low bioavailability of 11%. As an off-patent medication, Nimotop is widely available.","approvals":[{"date":"1988-12-28","orphan":true,"company":"","regulator":"FDA"}],"brandName":"Nimotop","ecosystem":[{"indication":"Subarachnoid intracranial hemorrhage","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Voltage-dependent L-type calcium channel subunit alpha-1F","novelty":"Follow-on","targets":[{"gene":"CACNA1F","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1F","protein":"Voltage-dependent L-type calcium channel subunit alpha-1F"},{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"NR1I2","source":"DrugCentral","target":"Nuclear receptor subfamily 1 group I member 2","protein":"Nuclear receptor subfamily 1 group I member 2"},{"gene":"SLC28A1","source":"DrugCentral","target":"Sodium/nucleoside cotransporter 1","protein":"Sodium/nucleoside cotransporter 1"},{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"CACNA1S","source":"DrugCentral","target":"Voltage-dependent L-type calcium channel subunit alpha-1S","protein":"Voltage-dependent L-type calcium channel subunit alpha-1S"},{"gene":"PDE1C","source":"DrugCentral","target":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C","protein":"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C"},{"gene":"CNR1","source":"DrugCentral","target":"Cannabinoid receptor 1","protein":"Cannabinoid receptor 1"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"}],"moaClass":"Calcium Channel Antagonists","modality":"Small Molecule","drugClass":"Dihydropyridine Calcium Channel Blocker [EPC]","explanation":"","oneSentence":"","technicalDetail":"Nimotop selectively binds to the voltage-dependent L-type calcium channel subunit alpha-1F, inhibiting the influx of calcium ions into smooth muscle cells and reducing vascular tone, thereby improving cerebral blood flow and reducing the risk of ischemic injury."},"commercial":{"launchDate":"1988","_launchSource":"DrugCentral (FDA 1988-12-28, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1937","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NIMODIPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIMODIPINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:58:24.795718","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:40:33.092871+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"felodipine","drugSlug":"felodipine","fdaApproval":"1991-07-25","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"isradipine","drugSlug":"isradipine","fdaApproval":"1990-12-20","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nicardipine","drugSlug":"nicardipine","fdaApproval":"1988-12-21","patentExpiry":"Dec 26, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nifedipine","drugSlug":"nifedipine","fdaApproval":"1981-12-31","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nisoldipine","drugSlug":"nisoldipine","fdaApproval":"1995-02-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clevidipine","drugSlug":"clevidipine","fdaApproval":"2008-08-01","patentExpiry":"Oct 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"nimodipine","indications":{"approved":[{"name":"Subarachnoid intracranial hemorrhage","source":"DrugCentral","snomedId":21454007,"regulator":"FDA","eligibility":"patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, Hunt and Hess Grades I to V"}],"offLabel":[{"name":"Essential tremor","source":"DrugCentral","drugName":"NIMODIPINE","evidenceCount":7,"evidenceLevel":"emerging"},{"name":"nerve regeneration after iatrogenic nerve injury","source":"DrugCentral","drugName":"NIMODIPINE","evidenceCount":2,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Azurity","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-class"},{"drugId":"felodipine","brandName":"felodipine","genericName":"felodipine","approvalYear":"1991","relationship":"same-class"},{"drugId":"isradipine","brandName":"isradipine","genericName":"isradipine","approvalYear":"1990","relationship":"same-class"},{"drugId":"nicardipine","brandName":"nicardipine","genericName":"nicardipine","approvalYear":"1988","relationship":"same-class"},{"drugId":"nifedipine","brandName":"nifedipine","genericName":"nifedipine","approvalYear":"1981","relationship":"same-class"},{"drugId":"nisoldipine","brandName":"nisoldipine","genericName":"nisoldipine","approvalYear":"1995","relationship":"same-class"},{"drugId":"clevidipine","brandName":"clevidipine","genericName":"clevidipine","approvalYear":"2008","relationship":"same-class"},{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06900998","phase":"PHASE2","title":"Pilot Study: Effects of Nimodipine on Alcohol Drinking","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-09-01","conditions":["Alcohol Use Disorder"],"enrollment":5,"completionDate":"2032-06-30"},{"nctId":"NCT07065903","phase":"","title":"Nimodipine Variability in SAH","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-05-13","conditions":["Subarachnoid Aneurysm Hemorrhage","Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":500,"completionDate":"2029-09"},{"nctId":"NCT06603181","phase":"NA","title":"Effect of Extracorporeal Shock Wave Therapy (ESWT) and Phonophoresis Treatment in Patients With Lateral Epicondylitis","status":"COMPLETED","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2024-09-25","conditions":["Lateral Epicondylitis","Extracorporeal Shock Wave Therapy","Phonophoresis"],"enrollment":60,"completionDate":"2025-04-30"},{"nctId":"NCT07305922","phase":"","title":"Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2025-12-01","conditions":["Subarachnoid Aneurysm Hemorrhage","Cerebral Vasospasm After Subarachnoid Hemorrhage"],"enrollment":200,"completionDate":"2030-12-31"},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT03925025","phase":"PHASE3","title":"Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2020-06-11","conditions":["Anticholinesterase Insecticide Poisoning","Pesticide Poisoning"],"enrollment":1728,"completionDate":"2025-04-30"},{"nctId":"NCT07144956","phase":"PHASE3","title":"Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-12-15","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":630,"completionDate":"2029-12-14"},{"nctId":"NCT06898125","phase":"NA","title":"Evaluation of Extracorporeal Shockwave Therapy and Complex Decongestive Therapy Results in Patients With Lipedema","status":"COMPLETED","sponsor":"Giresun University","startDate":"2023-09-01","conditions":["Lipedema","Pain"],"enrollment":33,"completionDate":"2025-06-01"},{"nctId":"NCT04923659","phase":"EARLY_PHASE1","title":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":["Low Intensity Focussed Ultrasound"],"enrollment":20,"completionDate":"2026-05"},{"nctId":"NCT07048522","phase":"NA","title":"Perioperative Intravenous Nimodipine Trial","status":"RECRUITING","sponsor":"University of Ioannina","startDate":"2025-05-19","conditions":["Colectomy","Open Surgery","Pain","Pain, Postoperative","Pain, Acute"],"enrollment":40,"completionDate":"2027-02-15"},{"nctId":"NCT07044232","phase":"PHASE4","title":"NICardipine for Fast Achievement of Systolic BP Targets in ICH","status":"NOT_YET_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-10-01","conditions":["Intracerebral Haemorrhage"],"enrollment":88,"completionDate":"2027-12-31"},{"nctId":"NCT06998368","phase":"NA","title":"A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans","status":"RECRUITING","sponsor":"Hans-Peter Landolt","startDate":"2024-10-22","conditions":["Mediation of 5G Effects on Sleep"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT06987721","phase":"","title":"Extracorporeal Shock-wave Therapy in Myofascial Pain Syndrome","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2022-01-18","conditions":["Myofacial Pain Syndrome"],"enrollment":57,"completionDate":"2024-08-01"},{"nctId":"NCT05534477","phase":"","title":"Verily Clinical Study Watch Analytical Validation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verily Life Sciences LLC","startDate":"2023-09-18","conditions":["Healthy Population","Chronic Disease"],"enrollment":100,"completionDate":"2025-06"},{"nctId":"NCT06321276","phase":"NA","title":"Investigation of the Efficiency of Radial Extracorporeal Shock Wave Therapy at Different Pulses in Carpal Tunnel Syndrome","status":"COMPLETED","sponsor":"Ahi Evran University Education and Research Hospital","startDate":"2023-11-01","conditions":["Carpal Tunnel Syndrome"],"enrollment":98,"completionDate":"2024-08-01"},{"nctId":"NCT06712329","phase":"NA","title":"Chronic Plantar Fasciitis: Which is More Effective? Prolotherapy/Extracorporeal Shock Wave Therapy?","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2023-10-01","conditions":["Chronic Plantar Fasciitis"],"enrollment":70,"completionDate":"2024-12-19"},{"nctId":"NCT04151433","phase":"NA","title":"Conservative Endometrioma Surgery","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-10-24","conditions":["Endometriosis Ovary","Endometrioma"],"enrollment":92,"completionDate":"2026-12"},{"nctId":"NCT06717633","phase":"PHASE3","title":"Comparison of Short-term Effects of Extracorporeal Shock Wave Therapy, Low-level Laser Therapy and Pulsed Electromagnetic Field Therapy in Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Istanbul Medeniyet University","startDate":"2024-01-01","conditions":["Knee Osteoarthritis"],"enrollment":120,"completionDate":"2025-03-30"},{"nctId":"NCT05995405","phase":"PHASE3","title":"Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grace Therapeutics Inc.","startDate":"2023-10-20","conditions":["Aneurysmal Subarachnoid Hemorrhage (aSAH)"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT06615882","phase":"NA","title":"Mechanical Intracranial Artery DilAtation Using Stent-retriever for Cerebral Vasospasm","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2024-09","conditions":["Intracranial Vasospasm"],"enrollment":10,"completionDate":"2027-04"},{"nctId":"NCT05118945","phase":"","title":"Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2021-03-03","conditions":["Type 1 Diabetes","Insulin Therapy"],"enrollment":50,"completionDate":"2021-12-28"},{"nctId":"NCT04148105","phase":"PHASE4","title":"Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2019-11-01","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":19,"completionDate":"2023-05-26"},{"nctId":"NCT04028596","phase":"PHASE2","title":"Measuring Blood Flow in the Brain After Epileptic Activity","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2019-12-05","conditions":["Epilepsy","Depression","Postictal Delirium","Electroconvulsive Therapy"],"enrollment":34,"completionDate":"2023-04-15"},{"nctId":"NCT04801953","phase":"PHASE2","title":"Nimodipine in Vestibular Schwanommas","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-05-04","conditions":["Vestibular Schwannoma"],"enrollment":30,"completionDate":"2024-04-09"},{"nctId":"NCT04649398","phase":"","title":"Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-11-25","conditions":["Subarachnoid Hemorrhage, Aneurysmal","Delayed Cerebral Ischemia","Vasospasm, Cerebral"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT05418348","phase":"PHASE1","title":"Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"Grace Therapeutics Inc.","startDate":"2021-08-26","conditions":["Aneurysmal Subarachnoid Hemorrhage"],"enrollment":58,"completionDate":"2022-02-24"},{"nctId":"NCT06007573","phase":"NA","title":"Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia","status":"COMPLETED","sponsor":"Yuzhen Pan","startDate":"2021-02-01","conditions":["Post-stroke Dementia"],"enrollment":40,"completionDate":"2023-08-15"},{"nctId":"NCT05689593","phase":"NA","title":"Comparison of Low-intensity Extracorporeal Shockwave Therapy and Low-intensity Laser Effects in Adhesive Capsulitis","status":"COMPLETED","sponsor":"Ahi Evran University Education and Research Hospital","startDate":"2023-01-21","conditions":["Adhesive Capsulitis"],"enrollment":65,"completionDate":"2023-08-02"},{"nctId":"NCT03671525","phase":"EARLY_PHASE1","title":"Cognitive Effects of Nimodipine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-10-05","conditions":["Schizophrenia","Schizo Affective Disorder"],"enrollment":18,"completionDate":"2023-05-12"},{"nctId":"NCT04100824","phase":"PHASE2","title":"Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-01-11","conditions":["Subarachnoid Hemorrhage"],"enrollment":40,"completionDate":"2023-01-12"},{"nctId":"NCT05889208","phase":"NA","title":"Prophylactic Permanent Pacemaker in Patients With Right Bundle Branch Block Undergoing Transcatheter Aortic Valve Implantation","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2023-12-01","conditions":["Aortic Stenosis","Right Bundle-Branch Block"],"enrollment":320,"completionDate":"2027-12-01"},{"nctId":"NCT01962818","phase":"NA","title":"High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-01","conditions":["Respiratory Distress Syndrome In Premature Infants","Bronchopulmonary Dysplasia","Ventilator-Induced Lung Injury","Functional Residual Capacity"],"enrollment":16,"completionDate":"2023-01-01"},{"nctId":"NCT05627921","phase":"NA","title":"The Effect of Botulinum Toxin and ESWT Applications on Spasticity and Functionality in Cerebral Palsy Patients","status":"UNKNOWN","sponsor":"Marmara University","startDate":"2022-11-15","conditions":["Cerebral Palsy, Spastic"],"enrollment":40,"completionDate":"2023-07-15"},{"nctId":"NCT04440748","phase":"NA","title":"Feasibility Study and Pilot RCT Into the Use of a Novel Technology to Train Sitting Balance and Trunk Control","status":"COMPLETED","sponsor":"Jan Kool","startDate":"2021-04-08","conditions":["Stroke"],"enrollment":32,"completionDate":"2022-09-12"},{"nctId":"NCT04311840","phase":"","title":"Impact of Nimodipine on Sublingual Microcirculation in Patients With Hemorrhage - a Prospective Monocentric Observational Study","status":"UNKNOWN","sponsor":"University Hospital Hradec Kralove","startDate":"2019-11-01","conditions":["Subarachnoid Hemorrhage"],"enrollment":30,"completionDate":"2022-12-31"},{"nctId":"NCT04917393","phase":"NA","title":"Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive","status":"UNKNOWN","sponsor":"Metavention","startDate":"2021-09-13","conditions":["Hypertension","Type 2 Diabetes","Metabolic Syndrome"],"enrollment":45,"completionDate":"2023-10-01"},{"nctId":"NCT03718780","phase":"NA","title":"Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise","status":"UNKNOWN","sponsor":"Centre Hospitalier Metropole Savoie","startDate":"2019-02-22","conditions":["Pulmonary Disease, Chronic Obstructive","Lung Diseases, Interstitial","Chronic Heart Failure","Pulmonary Arterial Hypertension","Hyperventilation Syndrome","Healthy"],"enrollment":105,"completionDate":"2024-02-22"},{"nctId":"NCT05131867","phase":"PHASE2","title":"Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2021-11-24","conditions":["Oral Nimodipine","Milrinone","Vascular Spasm After Traumatic Subarachnoidhaemorrhage"],"enrollment":30,"completionDate":"2022-05-24"},{"nctId":"NCT05246800","phase":"NA","title":"The Effectiveness of a Mindfulness Application on Perceived Stess","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2018-03-01","conditions":["mHealth","Mindfulness","Stress","Burnout"],"enrollment":587,"completionDate":"2019-01-01"},{"nctId":"NCT05182619","phase":"EARLY_PHASE1","title":"Stellate Block Versus Nimodipine Infusion for Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-01-01","conditions":["Traumatic Brain Injury"],"enrollment":60,"completionDate":"2023-04-01"},{"nctId":"NCT00000738","phase":"PHASE1","title":"Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["AIDS Dementia Complex","HIV Infections"],"enrollment":36,"completionDate":"1994-06"},{"nctId":"NCT03288766","phase":"","title":"SHERLOCK 3CG™ Diamond Tip Confirmation System","status":"TERMINATED","sponsor":"C. R. Bard","startDate":"2018-04-19","conditions":["Indication for Peripheral Intravenous Catheterization","Atrial Flutter","Premature Atrial Contraction","Premature Ventricular Contraction","Premature Junctional Contraction","Tachycardia","Atrioventricular Block","Bundle-Branch Block"],"enrollment":232,"completionDate":"2021-06-15"},{"nctId":"NCT04941846","phase":"","title":"The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2013-01","conditions":["Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":296,"completionDate":"2023-01"},{"nctId":"NCT01959009","phase":"NA","title":"High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Blood Oxygenation and Stability of Oxygenation","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2014-08","conditions":["Respiratory Distress Syndrome, Newborn","Bronchopulmonary Dysplasia","Ventilator Induced Lung Injury"],"enrollment":16,"completionDate":"2022-06"},{"nctId":"NCT01672801","phase":"NA","title":"Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT","status":"COMPLETED","sponsor":"Boston IVF","startDate":"2012-09","conditions":["Unexplained Infertility","Polycystic Ovarian Syndrome","Anovulatory"],"enrollment":18,"completionDate":"2014-04"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT03792945","phase":"PHASE4","title":"Comparison of the Efficacy of Corticosteroid Injection and ESWT in Patients With CTS","status":"COMPLETED","sponsor":"Ahi Evran University Education and Research Hospital","startDate":"2019-01-20","conditions":["Carpal Tunnel Syndrome","Tenosynovitis"],"enrollment":72,"completionDate":"2019-05-29"},{"nctId":"NCT04309708","phase":"NA","title":"Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy","status":"COMPLETED","sponsor":"B. Braun Medical International Trading Company Ltd.","startDate":"2018-05-01","conditions":["Subarachnoid Hemorrhage"],"enrollment":300,"completionDate":"2019-09-08"},{"nctId":"NCT04224376","phase":"NA","title":"Improving Maximal Strength in the Initial Postoperative Phase After Anterior Cruciate Ligament Reconstruction Surgery: Randomized Controlled Trial of an App-Based Serious Gaming Approac","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2016-04-01","conditions":["Anterior Cruciate Ligament Rupture"],"enrollment":26,"completionDate":"2018-10-01"},{"nctId":"NCT03228498","phase":"PHASE2","title":"Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2017-05-02","conditions":["Vascular Cognitive Impairment"],"enrollment":62,"completionDate":"2019-07-09"},{"nctId":"NCT04216992","phase":"","title":"Value of Three-dimensional Rotational Epidurography on Percutaneous Epidural Adhesiolysis","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2018-01-04","conditions":["Failed Back Surgery Syndrome","Spinal Stenosis"],"enrollment":30,"completionDate":"2019-12-06"},{"nctId":"NCT02537080","phase":"NA","title":"The Effect of Nimodipine on the Postoperative Cognitive Dysfunction","status":"TERMINATED","sponsor":"University Hospital Hradec Kralove","startDate":"2015-09","conditions":["Mild Cognitive Impairment"],"enrollment":15,"completionDate":"2017-12"},{"nctId":"NCT03150524","phase":"PHASE4","title":"RCVS: The Rational Approach to Diagnosis and Treatment","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2017-07-01","conditions":["Reversible Cerebral Vasoconstriction Syndrome"],"enrollment":0,"completionDate":"2019-05-31"},{"nctId":"NCT02991157","phase":"","title":"Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases","status":"COMPLETED","sponsor":"National Institute of Mental Health and Neuro Sciences, India","startDate":"2016-12","conditions":["Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":25,"completionDate":"2018-12"},{"nctId":"NCT01551368","phase":"PHASE2","title":"Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients","status":"TERMINATED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2012-12","conditions":["Infertility"],"enrollment":12,"completionDate":"2017-07"},{"nctId":"NCT03794843","phase":"EARLY_PHASE1","title":"Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers","status":"UNKNOWN","sponsor":"Shenyang Dongxing Pharmaceutical Technology Co., Ltd.","startDate":"2018-08-23","conditions":["Bioavailability","Safety Issues","Ischemic Cerebrovascular Disease"],"enrollment":26,"completionDate":"2019-06"},{"nctId":"NCT02893826","phase":"PHASE1","title":"Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH","status":"TERMINATED","sponsor":"Edge Therapeutics Inc","startDate":"2016-09","conditions":["Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":6,"completionDate":"2018-03"},{"nctId":"NCT02790632","phase":"PHASE3","title":"Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage","status":"TERMINATED","sponsor":"Edge Therapeutics Inc","startDate":"2016-07","conditions":["Subarachnoid Hemorrhage, Aneurysmal"],"enrollment":374,"completionDate":"2018-06"},{"nctId":"NCT02248233","phase":"PHASE4","title":"Nimodipine for Treating Acute Massive Cerebral Infarction","status":"COMPLETED","sponsor":"Fengtian Hospital","startDate":"2014-10","conditions":["Cerebral Infarction"],"enrollment":72,"completionDate":"2015-09"},{"nctId":"NCT01893190","phase":"PHASE1,PHASE2","title":"Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage","status":"COMPLETED","sponsor":"Edge Therapeutics Inc","startDate":"2013-09","conditions":["Ruptured Cerebral Aneurysm","Ruptured Berry Aneurysm"],"enrollment":73,"completionDate":"2016-01"},{"nctId":"NCT02774031","phase":"NA","title":"Comparison of Gas Consumption From Two Different Anesthesia Machines","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2016-05","conditions":["Male Urogenital Diseases","Female Urogenital Diseases"],"enrollment":147,"completionDate":"2017-10-20"},{"nctId":"NCT00000280","phase":"PHASE1","title":"Glutaminergic Agents for Cocaine Abuse - 5","status":"COMPLETED","sponsor":"Yale University","startDate":"1994-09","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":"1999-08"},{"nctId":"NCT00000332","phase":"PHASE2","title":"High Dose Nimodipine Treatment Adjunct - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1998-05","conditions":["Cocaine-Related Disorders"],"enrollment":0,"completionDate":"2000-04"},{"nctId":"NCT03028090","phase":"","title":"Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2013-11","conditions":["Indication for Peripheral Intravenous Catheterization"],"enrollment":182,"completionDate":"2014-11"},{"nctId":"NCT00781326","phase":"PHASE4","title":"Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2008-08","conditions":["Depression"],"enrollment":9,"completionDate":"2009-02"},{"nctId":"NCT01835665","phase":"PHASE1","title":"Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2013-03","conditions":["Progranulin Mutation Carriers"],"enrollment":8,"completionDate":"2016-05"},{"nctId":"NCT02165644","phase":"PHASE2","title":"Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2015-09","conditions":["Acute Cerebrovascular Accident","Vasospasm"],"enrollment":0,"completionDate":"2015-09"},{"nctId":"NCT00004399","phase":"NA","title":"Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1995-09","conditions":["Pre-eclampsia"],"enrollment":2000,"completionDate":"2000-08"},{"nctId":"NCT02041819","phase":"PHASE2","title":"Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2014-02","conditions":["Squamous Cell Carcinoma of Esophagus"],"enrollment":0,"completionDate":"2017-01"},{"nctId":"NCT00814658","phase":"PHASE4","title":"The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2008-06","conditions":["Dementia"],"enrollment":22,"completionDate":"2009-10"},{"nctId":"NCT01138683","phase":"PHASE3","title":"Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-02","conditions":["Acute Decompensated Heart Failure"],"enrollment":1,"completionDate":"2011-12"},{"nctId":"NCT01220622","phase":"PHASE4","title":"Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes","status":"UNKNOWN","sponsor":"Ministry of Science and Technology of the People´s Republic of China","startDate":"2010-10","conditions":["Stroke","Mild Cognitive Impairment"],"enrollment":656,"completionDate":"2012-07"},{"nctId":"NCT01206283","phase":"NA","title":"A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.","status":"COMPLETED","sponsor":"University of Sarajevo","startDate":"2006-01","conditions":["Brain Injuries","Subarachnoid Hemorrhage"],"enrollment":60,"completionDate":"2008-07"},{"nctId":"NCT00001478","phase":"","title":"Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1994-10","conditions":["Healthy","Mood Disorders"],"enrollment":170,"completionDate":"2001-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Solution","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Nimodipine"},{"form":"CAPSULE, LIQUID FILLED","route":"ORAL","productName":"Nimodipine"},{"form":"SOLUTION","route":"ORAL","productName":"Nymalize"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147543","MMSL":"109672","NDDF":"000713","UNII":"57WA9QZ5WH","VUID":"4019390","CHEBI":"CHEBI:7575","VANDF":"4019390","INN_ID":"4528","RXNORM":"1423768","UMLSCUI":"C0028094","chemblId":"CHEMBL1428","ChEMBL_ID":"CHEMBL255033","KEGG_DRUG":"D00438","DRUGBANK_ID":"DB00393","PDB_CHEM_ID":" 6U9","PUBCHEM_CID":"4497","SNOMEDCT_US":"387502003","IUPHAR_LIGAND_ID":"2523","MESH_DESCRIPTOR_UI":"D009553"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Azurity","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.3 hours","clearance":"15.0 mL/min/kg","bioavailability":"11%","fractionUnbound":"0.016%","volumeOfDistribution":"1.1 L/kg"},"publicationCount":4552,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C08CA06","allCodes":["C08CA06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 26","pmid":"41886253","title":"Commentary on: \"Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage\".","journal":"Neurocritical care"},{"date":"2026 Mar 26","pmid":"41886251","title":"Response to Letter by Michael Veldeman Regarding Article \"Impact of Nimodipine-Induced Blood Pressure Reductions on Cerebral Autoregulation and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage\".","journal":"Neurocritical care"},{"date":"2026 Mar 26","pmid":"41882452","title":"Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.","journal":"Neurosurgical review"},{"date":"2026","pmid":"41855149","title":"Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study.","journal":"PloS one"},{"date":"2026 Mar 17","pmid":"41843337","title":"Unrevealing possible mechanism of Riluzole, Salsalate and Nimodipine in Alzheimer's disease: multi-target network pharmacological perspective.","journal":"Inflammopharmacology"}],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Alkem Labs Ltd","Annora Pharma","Bionpharma","Heritage","Sofgen Pharms","Sun Pharm Inds Inc","Thepharmanetwork Llc"],"status":"approved","companyName":"Azurity","companyId":"","modality":"Small molecule","firstApprovalDate":"1988","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-12-28T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-05-02T00:00:00.000Z","mah":"HERITAGE","brand_name_local":null,"application_number":"ANDA077811"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-02-28T00:00:00.000Z","mah":"BIONPHARMA","brand_name_local":null,"application_number":"ANDA076740"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-04-09T00:00:00.000Z","mah":"AZURITY","brand_name_local":null,"application_number":"NDA203340"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-09T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":null,"application_number":"ANDA216937"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:40:33.092871+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}